Company interested in acquiring novel product for orphan tumour type in a tight turnaround window, but pricing a large uncertainty
Examined pricing and reimbursement analogues of therapeutics for similar- prevalence conditions. Conducted a regression analysis that predicted the likely reimbursed price for a novel oncologic given a specific prevalence. Applied this, as well as early cost-utility analysis and payer interviews to support a commercially-viable price for the deal
All work was completed in time for Board meeting and approval, resulting in acquisition of the asset
Organisation interested in understanding the possibility and accuracy of automating a literature review for a health technology assessment (HTA) submission
Partnered with professors from the University of Cambridge Computer Lab to develop a pilot using natural language processing in Python. Compared accuracy vs already published Cochrane reviews
Approximately 80% overlap in article hit rate with Cochrane publication. Currently refining program to improve accuracy and automate analysis of extracted data. Poster presented at ISPOR Europe 2019 Congress in Copenhagen and available here
Company interested in improving customer/external perceptions and relationships by developing a more transparent health economic model in R
Two independent modellers, one of whom adapted existing Markov model in Excel (VBA) into R, while other developed model in R from scratch. Cross-validated to arrive at final model, which was then reviewed and approved by internal and external stakeholders
Received positive feedback from stakeholders around improved transparency and greater trust in the model results